How Ph.D. was paid
$2.5M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Stock | Incentive | Other | Total |
|---|---|---|---|---|---|
| Jasbir Seehra, Ph.D.President and Chief Executive Officer | $700,000 | $1,426,280 | $398,125 | $15,799 | $2,540,204 |
| Keith RegnanteChief Financial Officer | $470,382 | $464,640 | $164,850 | $14,000 | $1,113,872 |
| Esther Cho, Esq.Chief Legal Officer | $459,192 | $464,640 | $161,000 | $14,000 | $1,098,832 |
| Christopher RovaldiFormer President and Chief Operating Officer | $578,923 | $871,200 | — | $25,990 | $1,476,114 |
What changed and why
- $2.5MJasbir Seehra received total compensation of $2,540,204 in 2025, representing a decrease from the prior year.
- The company decided to exclusively prioritize the clinical advancement of rinvatercept.
- Christopher Rovaldi ceased his employment with the company effective August 18, 2025.
- Performance-based incentive compensation was earned by NEOs under the annual performance-based bonus program.
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.